PALO ALTO, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today that chairman and chief executive officer, Belinda Tsao Nivaggioli, Ph.D., will present an overview of the company's ongoing clinical development programs at the 10th Annual BIO CEO & Investor Conference to be held February 11-13, 2008 at the Waldorf Astoria Hotel in New York City. Dr. Tsao Nivaggioli will be presenting on Monday, February 11 at 12:30 p.m. (ET) in the East Foyer. For more information on this event please visit: http://ceo.bio.org/opencms/ceo/2008/about/index.jsp
To participate in a live audio webcast of Dr. Tsao Nivaggioli's presentation please log onto Avicena's corporate website at http://www.avicenagroup.com at least fifteen minutes prior to the start of the presentation to download any necessary materials. An archive of this event will be available in the investor relations section of the website for 90 days.
Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto,
California based late-stage biotechnology company that develops central
nervous system therapeutics for neurodegenerative disorders. The company's
core technologies, supported by a robust IP portfolio, have broad
applications in both pharmaceuticals and dermaceuticals. Avicena's
pharmaceutical program centers on rare neurological disorders (orphan
diseases). Near term, the company plans to initiate a confirmatory Phase
III trial in ALS and a Phase III trial in Huntington's disease to accompany
the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science
is well established and its products are safe and well tolerated. Unlike
traditional biotechnology companies,
|SOURCE Avicena Group, Inc.|
Copyright©2008 PR Newswire.
All rights reserved